Drug Trial Radar · NCT05787613
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Jul 10, 2023
Primary completion
Feb 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) Patients
Conditions
- NSCLC Stage IV
Interventions
HLX26Drug
Anti-LAG-3 monoclonal Antibody Injection
SerplulimabDrug
anti-PD-1 humanized monoclonal antibody injection
Chemotherapy drugDrug
non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) (Part 1)Time frame: from day1 to day 21
- Maximum Tolerated Dose (MTD) (Part 1)Time frame: from day1 to day 21
- Objective Response Rate (ORR) per RECIST 1.1 as Assessed by IRRC ( Part 2)Time frame: approximately up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.